Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has received a consensus rating of “Buy” from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $21.75.

Several research analysts recently issued reports on the company. Jefferies Group LLC reissued a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, May 25th. Oppenheimer Holdings, Inc. assumed coverage on Vanda Pharmaceuticals in a research note on Wednesday, April 12th. They issued an “outperform” rating and a $21.00 price objective on the stock. TheStreet raised Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Friday, May 12th. Zacks Investment Research cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, June 7th. Finally, CIBC reaffirmed an “outperform” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th.

A number of hedge funds have recently made changes to their positions in the stock. Virginia Retirement Systems ET AL bought a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $193,000. Capital Fund Management S.A. bought a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $195,000. AQR Capital Management LLC bought a new stake in shares of Vanda Pharmaceuticals during the fourth quarter valued at about $223,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $196,000. Finally, Algert Global LLC boosted its stake in shares of Vanda Pharmaceuticals by 11.8% in the first quarter. Algert Global LLC now owns 18,223 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 1,927 shares during the period. 92.51% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Vanda Pharmaceuticals Inc. (VNDA) Given Average Rating of “Buy” by Analysts” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/21/vanda-pharmaceuticals-inc-vnda-given-average-rating-of-buy-by-analysts.html.

Vanda Pharmaceuticals (VNDA) traded up 0.92% on Friday, hitting $16.45. The stock had a trading volume of 67,514 shares. The firm’s market capitalization is $732.88 million. The stock’s 50-day moving average is $15.39 and its 200 day moving average is $14.54. Vanda Pharmaceuticals has a 1-year low of $10.98 and a 1-year high of $18.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.04. Vanda Pharmaceuticals had a negative return on equity of 10.42% and a negative net margin of 8.85%. The firm had revenue of $37.42 million during the quarter, compared to the consensus estimate of $38.35 million. On average, equities research analysts predict that Vanda Pharmaceuticals will post ($0.70) earnings per share for the current fiscal year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.